Current medical management of diabetic foot infections

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 11, 2010, Pages 1293-1305

  Kosinski, Mark A ^a   Lipsky, Benjamin A ^b  

^a NEW YORK COLLEGE OF PODIATRIC MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

empiric therapy; foot infections; multidrug resistant organisms; osteomyelitis; polymicrobial infections; severity of infection; soft tissue infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CARBAPENEM; CEFALEXIN; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DICLOXACILLIN; DOXYCYCLINE; ERTAPENEM; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TELAVANCIN; TIGECYCLINE; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ACIDOSIS; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIUM EXAMINATION; BONE BIOPSY; BONE INFECTION; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIABETIC FOOT; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; HYPERPHOSPHATEMIA; INTERMETHOD COMPARISON; LACTIC ACIDOSIS; LEG AMPUTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NONHUMAN; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; RECURRENT INFECTION; REMISSION; REVIEW; RISK FACTOR; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS; STREPTOCOCCUS INFECTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT PLANNING; UREA BLOOD LEVEL; UREMIA; VOMITING; WOUND HEALING;

AMPUTATION; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DIABETIC FOOT; HUMANS; OSTEOMYELITIS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS;

EID: 78349241448     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.122     Document Type: Review

References (113)

1. Bloomgarden Z. American Diabetes Association 60th Scientifc Sessions 2000. The Diabetic Foot. Diabetes Care 24, 946-951 (2001).
2. Boyko EJ, Lipsky BA. Infection and diabetes mellitus. In: Diabetes in America (2nd Edition). Harris I (Ed.). NIH, Washington, DC, USA, 485-496 (1995).
3. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care 29, 1288-1293 (2006).
4. Pecoraro RE. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes 40, 1305-1313 (1991).
5. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 13, 513-521 (1990).
6. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004).
7. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26, 510-513 (2003).
8. Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet. Med. 14, 29-34 (1997).
9. Alexiewicz JM, Kumar D, SmogorzewskiM, Klin M, Massry SG. Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann. Intern. Med. 123, 919-924 (1995).
10. The Foot. Helal B, Wilson D. (Eds). Churchill Livingstone, London, UK, 710-738 (1988).
11. Disorders of the Foot. Helfet A, Grudel D (Eds). JB Lippincot Co., PA, USA, 205-215 (1980).
12. Disorders of the Foot and Ankle. Medical and Surgical Management. Volume 1 (2nd Edition). Jhass MH (Ed.). WB Saunders, London, UK, 484-519 (1991).
13. Armstrong DG, Liswood PJ, Todd WF. Prevalence of mixed infections in the diabetic pedal wound. A retrospective review of 112 infections. J. Am. Podiatr. Med. Assoc. 85, 533-537 (1995).
14. Bowling FL, Jude EB, Boulton AJ. MRSA and diabetic foot wounds: contaminating or infecting organisms? Curr. Diab. Rep. 9, 440-444 (2009).
15. Citron DM, Goldstein EJ, Merriam CV et al. Bacteriology of moderate to severe diabetic foot infections and in vitro activity of antimicrobial agents. J. Clin. Microbiol. 45, 2819-2828 (2007).
16. Gadepalli R, Dhawan B, Sreenivas V. A clinic-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care 8, 1727-1732 (2006).
17. Reyzelman AM, Lipsky BA, Hadi SA, Harkless LB, Armstrong DG. The increased prevalence of severe necrotizing infections caused by non-group A streptococci. J. Am. Podiatr. Med. Assoc. 89, 454-457 (1999).
18. Brook I. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes. J. Med. Microbiol. 27, 191-198 (1988).
19. Kelly MJ. Wound infection: a controlled clinical and experimental demonstration of synergy between aerobic (Escherichia coli) and anaerobic (Bacteroides fragilis) bacteria. Ann. R. Coll. Surg. Engl. 62, 52-59 (1980).
20. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/ tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 366, 1695-1703 (2005).
21. Raja NS. Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases. J. Microbiol. Immunol. Infect. 40, 39-44 (2007).
22. Lipsky BA, Berendt AR, Deery HG et al. Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections.Clin. Infect. Dis. 39, 885-910 (2004).
23. Bessman AN, Geiger PJ, Canawati H. Prevalence of Corynebacteria in diabetic foot infections. Diabetes Care 15, 1531-1533 (1992).
24. Hartemann-Heurtier A, Senneville E. Diabetic foot osteomyelitis. Diabetes Metab. 34, 87-95 (2008).
25. Galkowska H, Podbielska A, Olszewski WL et al. Epidemiology and prevalence of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis in patients with diabetic foot ulcers: focus on the differences between species isolated from individuals with ischemic vs. neuropathic foot ulcers. Diabetes Res. Clin. Pract. 84, 187-193 (2009).
26. Lipsky B. Medical treatment of diabetic foot infections. Clin. Infect. Dis. 39, S104-S114 (2004). (Pubitemid 39050506)
27. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet. Med. 20, 159-161 (2003).
28. Lipsky BA, Tabak Y P, Johannes RS, Vo L, Hyde L, Weigelt JA. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia 53(5), 914-923 (2010).
29. Tentolouris N, Petrikkos G, Vallianou N et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin. Microbiol. Infect. 12, 186-189 (2006).
30. Yates C, May K, Hale T et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care 32, 1907-1909 (2009).
31. Stanaway S, Johnson D, Moulik P, Gill G. Methicillin-resistant Staphylococcus aureus (MRSA) isolation from diabetic foot ulcers correlates with nasal MRSA carriage. Diabetes Res. Clin. Pract. 75, 47-50 (2007).
32. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res. Clin. Pract. 80, 344-351 (2008).
33. Graves SF, Kobayashi SD, Deleo FR. Community-associated methicillin-resistant Staphylococcus aureus immune evasion and virulence. J. Mol. Med. 88(2), 109-114 (2010).
34. Hartemann-Heurtier A, Robert J, Jacqueminet S et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet. Med. 21, 710-715 (2004).
35. Richard JL, Sotto A, Jourdan N et al. Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabetes Metabolism 34, 363-369 (2008).
36. Varaiya AY, Dogra JD, Kulkarni MH, Bhalekar PN. Extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae in diabetic foot infections. Indian J. Pathol. Microbiol. 51, 370-372 (2008).
37. Pellizzer G, Strazzabosco M, Presi S et al. Deep tissue biopsy vs. superfcial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet. Med. 18, 822-827 (2001).
38. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch. Intern. Med. 150, 790-797 (1990).
39. Sapico FL, Witte JL, Canawati HN, Montgomerie JZ, Bessman AN. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev. Infect. Dis. 6, S171-S176 (1984).
40. Sharp GS, Bessman AN, Wagner FW Jr, Garland D, Reece E. Microbiology of superfcial and deep tissues in infected diabetic gangrene. Surg. Gynecol. Obstet. 149, 217-219 (1979).
41. Sapico FL, Canawati HN, Witte JL, Montogomerie JZ, Wagner FW Jr, Bessman AN. Quantitative aerobic and anaerobic bacteriology of infected diabetic feet. Clin. Microbiol. 12, 413-420 (1980).
42. Chakraborti C, Le C, Yanofsky A. Sensitivity of superfcial cultures in lower extremity wounds. J. Hosp. Med. 5, 415-420 (2010).
43. Lipsky BA, International consensus group on diagnosing and treating the infected diabetic foot. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab. Res. Rev. 20(Suppl. 1), S68-S77 (2004).
44. Gardner SE, Frantz RA. Wound bioburden and infection-related complication in diabetic foot ulcers. Biol. Res. Nurs. 10, 44-53 (2008).
45. Teh J, Berendt T, Lipsky BA. Rational Imaging. Investigating suspected bone infection in the diabetic foot. BMJ 339, b4690 (2009).
46. Bernard L, Uçkay I, Vuagnat A et al. Two consecutive deep sinus tract cultures predict the pathogen of osteomyelitis. Int. J. Infect. Dis. 14, e390-e393 (2010).
47. Agarwal S, Zahid M, Sherwani MK, Abbas M, Huda N, Kahn AO. Comparison of the results of sinus track culture and sequestrum culture in chronic osteomyelitis. Acta Orthop. Belg. 71, 209-212 (2005).
48. Ulug M, Avaz C, Celen MK, Gevik MF, Hosoglu S, Necmioglu S. Are sinus track cultures reliable for identifying the cuasative agent in chronic osteomyelitis? Arch. Orthop. Trauma Surg. 129, 1565-1570 (2009).
49. Berendt AR, Peters EJ, Bakker K et al Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab. Res. Rev. 24, S145-S161 (2008).
50. Butalia S, Palda VA, Sargeant RJ, Detsky AS, Mourad O. Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA 299, 806-813 (2008).
51. Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. Clin. Infect. Dis. 47, 519-527 (2008).
52. Senneville E, Lombart A, Beltrand E et al Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care 31, 637-642 (2008).
53. Norden CW Lessons learned from animal models of osteomyelitis. Rev. Infect. Dis. 10, 103-110 (1988).
54. Mader JT Animal models of osteomyelitis. Am. J. Med. 78, 213-217 (1985).
55. Jeffcoate WJ, Lipsky BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin. Infect. Dis. 39, S115-S122 (2004).
56. Raad I, Hanna H, Jiang Y et al Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in bioflm. Antimicrob. Agents Chemother. 51, 1656-1660 (2007).
57. Yamaoka T The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA. J. Infect. Chemother. 13, 141-146 (2007).
58. Embil JM, Rose G, Trepman E et al. Oral antimicrobial therapy for diabetic foot osteomyelitis. Foot Ankle Int. 27, 771-779 (2006). (Pubitemid 44497843)
59. Game FL, Jeffcoate WJ. Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia 51, 962-967 (2008).
60. Cunha BA. Oral and IV to PO switch antibiotic therapy of hospitalized patients with serious infections. Scand. J. Infect. Dis. 40(11-12), 1004-1006 (2008).
61. Waagsbø B, Sundøy A, Paulsen EQ. Reduction of unnecessary IV. antibiotic days using general criteria for antibiotic switch. Scand. J. Infect. Dis. 40, 468-473 (2008).
62. Daver NG, Shelburne SA, Atmar RL et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J. Infect. 54, 539-544 (2007).
63. Gomis M, Barberán J, Sánchez B, Khorrami S, Borja J, García-Barbal J. Oral ofoxacin versus parenteral imipenem- cilastatin in the treatment of osteomyelitis. Rev. Esp. Quimioter 12, 244-249 (1999).
64. Yilmaz G, Aydin K, Iskender S, Caylan R, Koksal I. Detection and prevalence of inducible clindamycin resistance in staphylococci. J. Med. Microbiol. 56, 342-345 (2007).
65. Invanz (ertapenem for injection) prescribing information. Merck and Co., Inc. Whitehouse Station. NJ, USA (March 2010).
66. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell KL, Gesser RM. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Clin. Infect. Dis. 35, S119-S125 (2002).
67. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42, S35-S39 (2006).
68. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin. Infect. Dis. 45, S191-S195 (2007).
69. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: effcacy and toxicity. Arch. Intern. Med. 166, 2138-2144 (2006).
70. Rybak MJ, Lomaestro BM, Rotscahfer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49, 325-327 (2009).
71. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am. J. Med. 123, 182.e1-e7 (2010).
72. Jefferson KK, Goldmann DA, Pier GB. Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus bioflms. Antimicrob. Agents Chemother. 49, 2467-2473 (2005).
73. Rose WE, Poppens PT Impact of bioflm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylo cco ccus aureus. J. Antimicrob. Chemother. 63, 485-488 (2008).
74. Dunne WM Jr. Effects of subinhibitory concentrations of vancomycin or cefamandole on bioflm production by coagulase-negative staphylococci. Antimicrob. Agents Chemother. 34, 390-393 (1990).
75. Skhirtladze K, Hutschala D, Fleck T et al Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob. Agents Chemother. 50, 1372-1375 (2006).
76. Raad I, Hanna H, Jiang Y et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in bioflm. Antimicrob. Agents Chemother. 51, 1656-1660 (2007).
77. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin. Microbiol. Rev. 23, 14-34 (2010).
78. Yamaoka T The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA. J. Infect. Chemother. 13, 141-146 (2007).
79. Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 49, 1072-1079 (2009).
80. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin- sensitive and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 195, 202-211 (2007).
81. Singh SR, Bacon AE 3rd, Young DC, Couch KA. In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53, 4495-4497 (2009).
82. Jacqueline C, Caillon J, Le Mabecque V et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J. Antimicrob. Chemother. 51, 857-864 (2003).
83. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207-208 (2001).
84. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/ amoxicillin-clavulanate. Clin. Infect. Dis. 38, 17-24 (2004).
85. Itani KM, Weigelt J, Li JZ, Dattagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 26, 442-448 (2005).
86. Senneville E, Legout L, Valette M et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J. Antimicrob. Chemother. 54, 798-802 (2004).
87. Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 46, 2723-2726 (2002).
88. Wu VC, Wang YT, Wang CY et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin. Infect. Dis. 42(1), 66-72 (2006).
89. Zyvox (linezolid) prescribing information. Pharmacia and Upjohn Company. Div. of Pfzer Inc. New York, NY, USA (December 2009).
90. Niwa T, Suzuki A, Sakakibara S et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin. Ther. 31, 2126-2133 (2009).
91. Tsuji Y, Hiraki Y, Matsumoto K et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J. Infect. Chemother. DOI: 10.1007/sl0156-010-0080-6 (2010) (Epub ahead of print).
92. Narita M, Tsuji BT, Yu VL. Linezolid- associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 27, 1189-1197 (2007).
93. Beekmann SE, Gilbert DN, Polgreen PM; IDSA Emerging Infections Network. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn. Microbiol. Infect. Dis. 62, 407-410 (2008).
94. Bosso JA. The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy 25, 55S-62S (2005).
95. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother. 55, 240-245 (2005).
96. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other p-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48, 2871-2875 (2004).
97. Traunmiiller F, Schintler M, Metzler J et al Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections./. Antimicrob. Chemother. DOI: 10.1093/jac/dkql09 (2010) (Epub ahead of print).
98. Cubicin (daptomycin) prescribing information. Cubist Pharmaceuticals Inc., Lexington, MA, USA (August 2010).
99. Testa RT, Petersen PJ, Jacobus NV et al. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother. 37, 2270-2277 (1993).
100. Garrison MW, Neumiller JJ, Setter SM. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant Gram-positive organisms. Clin. Ther. 27, 12-22 (2005).
101. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. 41, S333-S340 (2005).
102. Sotto A, Bouziges N, Jourdan N, Richard JL, Lavigne JP. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol. Biol. (Paris) 55, 398-406 (2007).
103. Tygacyl (tigecycline) prescribing information. Wyeth Pharmaceuticals Inc., Philadelphia, PA, USA (May 2010).
104. Passarell J, Ludwig E, Liolios K et al. Exposure-response analyses of tigecycline tolerability in healthy subjects. Diagn. Microbiol. Infect. Dis. 65, 123-129 (2009).
105. Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/ amoxicillin-clavulanate. /. Antimicrob. Chemother. 60, 370-376 (2007).
106. Stryjewski ME, Graham DR, Wilson SE et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis. 46, 1683-1693 (2008).
107. Nannini EC, Stryjewski ME, Corey GR. Ceftaroline for complicated skin and skin-structure infections. Expert Opin. Pharmacother. 11, 1197-1206 (2010).
108. Steed M, RybakJ. Ceftaroline: anew cephalosporin with activity against resistant Gram-positive pathogens. Pharmacotherapy 30, 375-389 (2010).
109. Corey GR, Wilcox M, Talbot GH et al Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis. 51, 641-650 (2010).
110. Jauregui LE, Babazadeh S, Seltzer E et al Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41, 1407-1415 (2005).
111. Busse K, Oltrogge K, Oxencis C, Peppard W Dalbavancin: a review of its use in the treatment of Gram-positive infections. Clin. Med. Insights Ther. 2, 7-13 (2010).
112. Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob. Agents Chemother. 54, 1338-1342 (2010).
113. Lipsky B, Berendt A, Deery H et al Infectious Disease Society of America. Guidelines for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 39, 885-910 (2004).